Insights into elastin fiber fragmentation: Mechanisms and treatment of aortic aneurysm in Marfan syndrome
Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder caused by
fibrillin 1 (FBN1) gene mutations that results in defects in the skeletal, ocular, and …
fibrillin 1 (FBN1) gene mutations that results in defects in the skeletal, ocular, and …
Oxidative stress-related susceptibility to aneurysm in Marfan's syndrome
J Rysz, A Gluba-Brzózka, R Rokicki, B Franczyk - Biomedicines, 2021 - mdpi.com
The involvement of highly reactive oxygen-derived free radicals (ROS) in the genesis and
progression of various cardiovascular diseases, including arrhythmias, aortic dilatation …
progression of various cardiovascular diseases, including arrhythmias, aortic dilatation …
Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol
A Mieremet, M van der Stoel, S Li, E Coskun… - Scientific reports, 2022 - nature.com
Patients with Marfan syndrome (MFS) develop thoracic aortic aneurysms as the aorta
presents excessive elastin breaks, fibrosis, and vascular smooth muscle cell (vSMC) death …
presents excessive elastin breaks, fibrosis, and vascular smooth muscle cell (vSMC) death …
Heterogenous improvements in endothelial function by sub-blood pressure lowering doses of ARBs result in major anti-aortic root remodeling effects
AY Tehrani, R Zhao, G Donen, P Bernatchez - Nitric Oxide, 2023 - Elsevier
Low basal nitric oxide (NO) production is associated with a dysfunctional endothelium and
vascular diseases. We have shown that some angiotensin II (AngII) receptor type 1 (AT1R) …
vascular diseases. We have shown that some angiotensin II (AngII) receptor type 1 (AT1R) …
Nitric oxide in the Marfan vasculature: Friend or foe?
AY Tehrani, MA Ciufolini, P Bernatchez - Nitric Oxide, 2021 - Elsevier
Marfan syndrome (MFS) is a connective tissue disorder caused by mutations in the FBN1
gene, which encodes fibrillin-1, a protein essential for the formation and stabilization of …
gene, which encodes fibrillin-1, a protein essential for the formation and stabilization of …
Losartan and metabolite EXP3179 activate endothelial function without lowering blood pressure in AT2 receptor KO mice
E Sauge, Z White, F Lizotte, C Yuen, NDP Atmuri… - European Journal of …, 2024 - Elsevier
Background We have documented profound release of nitric oxide (NO) and endothelium-
derived hyperpolarization factor (EDHF) by angiotensin II (ANGII) receptor 1 (AT1) blocker …
derived hyperpolarization factor (EDHF) by angiotensin II (ANGII) receptor 1 (AT1) blocker …
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
AY Tehrani, Z White, LW Tung, RRY Zhao, N Milad… - Scientific reports, 2022 - nature.com
There are no therapeutics that directly enhance chronic endothelial nitric oxide (NO)
release, which is typically associated with vascular homeostasis. In contrast, angiotensin II …
release, which is typically associated with vascular homeostasis. In contrast, angiotensin II …
主动脉夹层后血压管理的研究进展
李志勇， 王晶， 周雅丽， 袁东 - 协和医学杂志, 2024 - xhyxzz.pumch.cn
高血压(hypertension, HT) 可通过增加主动脉管壁张力和促使组织结构退化而诱发主动脉夹层(
aortic dissection, AD), 是AD 预后的显著影响因素, 也是最重要的可控因素. 研究表明, AD …
aortic dissection, AD), 是AD 预后的显著影响因素, 也是最重要的可控因素. 研究表明, AD …
Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Aortic Aneurysm Formation in Marfan Syndrome
H Yagi, H Akazawa, Q Liu, M Umei, H Kadowaki… - bioRxiv, 2022 - biorxiv.org
Background Marfan syndrome (MFS), an inherited disorder caused by FBN1 gene
mutations, causes fatal aortic aneurysm. Selective angiotensin II (Ang II) type 1 (AT1) …
mutations, causes fatal aortic aneurysm. Selective angiotensin II (Ang II) type 1 (AT1) …
Pleiotropism of losartan and its metabolites against cardiopulmonary diseases: small chemical differences, major biological impacts
E Sauge - 2024 - open.library.ubc.ca
Losartan and telmisartan are blood pressure (BP)-lowering angiotensin II (ANGII) type 1
receptor (AT1) blockers (ARBs) with unexpected therapeutic properties in settings not linked …
receptor (AT1) blockers (ARBs) with unexpected therapeutic properties in settings not linked …